HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
View All | Scroll Down Scroll Up
Quote:
Login Free Membership
Search:

Analyst Blog  

Buy 3SBio Up to $10

Share
March 18, 2009 |Comments: 0
Recommended this article (0)
SSRX | AMAG

3SBio Inc. (SSRX) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product EPIAO is the number 1 brand in China's EPO [erythropoietin] market.

Its second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deal with US-based AMAG Pharmaceuticals Inc. (AMAG) will boost its expansion into IV Iron market.

We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a price target of $10.

Read the full analyst report on SSRX

Read the full analyst report on AMAG

 
Add a Comment

Please login or register to post a comment

Email
Print
Share
Rate Pos
Rate Neg
Comment

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary Feb 10, 2012 13:18 pm ET
DJIA 12751.96  -138.50 -1.07%
NASD 2902.84  -24.39 -0.83%
S&P 500 1339.64  -12.31 -0.91%
Partner Center

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Profit Tracks
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns Trader
Insider Trader
Options Trader
Reitmeister Alert
Small Cap Trader
Turnaround Trader
Whisper Trader
Home Run Investor
Top 10 Stocks
Research Wizard
Zacks Premium
People & Picks
Zacks.com: About Zacks | Education | Advertise | Affiliate | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2011 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.